Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nuplazid (pimavanserin) is an atypical antipsychotic 5-HT2A receptor inverse agonist, which is being evaluated for the treatment of patients with schizophrenia.
Lead Product(s): Pimavanserin Tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: Nuplazid
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
ACP-101 (carbetocin) is a small molecule nasal spray acting as an Oxytocin receptor agonist, it is currently being investigated for the treatment of hyperphagia in Prader-Willi syndrome.
Lead Product(s): Carbetocin Acetate
Therapeutic Area: Genetic Disease Product Name: ACP-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
ACP-204 works primarily as an inverse agonist at the 5-HT2A receptor. ACP-204 is currently being developed for the treatment of Alzheimer's disease psychosis, for which there is a large unmet medical need and no FDA-approved medication.
Lead Product(s): ACP-204
Therapeutic Area: Neurology Product Name: ACP-204
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Nuplazid (pimavanserin) is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors, which is used treatment for Parkinson’s disease-related hallucinations and delusions who also have dementia.
Lead Product(s): Pimavanserin Tartrate
Therapeutic Area: Neurology Product Name: Nuplazid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Under the agreement, Acadia will acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591, an investigational synthetic analogue of cGP, for Rett syndrome and Fragile X syndrome.
Lead Product(s): Cyclo-Glycyl-proline Analog
Therapeutic Area: Genetic Disease Product Name: NNZ-2591
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Neuren Pharmaceuticals
Deal Size: $463.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement July 13, 2023
Details:
ACP-101 (carbetocin) is an investigational drug in the form of an intranasal formulation of carbetocin being developed for the treatment of hyperphagia in Prader-Willi syndrome (PWS).
Lead Product(s): Carbetocin Acetate
Therapeutic Area: Genetic Disease Product Name: ACP-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
Daybue (trofinetide) is a CYP3A4 inhibitor which helps to stimulate synaptic maturation and overcome the synaptic and neuronal immaturities that are characteristic of Rett syndrome pathophysiology.
Lead Product(s): Trofinetide
Therapeutic Area: Genetic Disease Product Name: Daybue
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
Daybue (trofinetide) is a CYP3A4 inhibitor which helps to stimulate synaptic maturation and overcome the synaptic and neuronal immaturities that are characteristic of Rett syndrome pathophysiology.
Lead Product(s): Trofinetide
Therapeutic Area: Genetic Disease Product Name: Daybue
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2023
Details:
NUPLAZID (Pimavanserin) is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors and prevents psychosis symptoms associated with Parkinson's Disease Psychosis.
Lead Product(s): Pimavanserin Tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: Nuplazid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
SLS-002 is intranasal racemic ketamine with two investigational new drug applications for the treatment of acute suicidal ideation and behavior in patients with major depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Seelos Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022